Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

Market Value Added (MVA)

Microsoft Excel

MVA

Bristol-Myers Squibb Co., MVA calculation

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Fair value of debt1 45,518 36,946 35,267 49,284 58,840
Operating lease liability 1,551 1,692 1,397 1,043 997
Market value of common equity 113,946 98,501 151,637 146,346 134,429
Preferred stock, $2 convertible series, par value $1 per share
Noncontrolling interest 53 55 57 60 60
Less: Marketable debt securities and equity investments 1,122 1,639 1,234 5,006 5,170
Market (fair) value of BMS 159,946 135,555 187,124 191,727 189,156
Less: Invested capital2 62,654 67,562 71,720 80,284 90,149
MVA 97,292 67,993 115,404 111,443 99,007

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Fair value of debt. See details »

2 Invested capital. See details »

Item Description The company
MVA Bristol-Myers Squibb Co. market (fair) value less invested capital. Bristol-Myers Squibb Co. MVA decreased from 2022 to 2023 but then increased from 2023 to 2024 not reaching 2022 level.

MVA Spread Ratio

Bristol-Myers Squibb Co., MVA spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Market value added (MVA)1 97,292 67,993 115,404 111,443 99,007
Invested capital2 62,654 67,562 71,720 80,284 90,149
Performance Ratio
MVA spread ratio3 155.28% 100.64% 160.91% 138.81% 109.83%
Benchmarks
MVA Spread Ratio, Competitors4
AbbVie Inc. 483.23% 438.96% 297.39% 253.64% 172.70%
Amgen Inc. 238.60% 213.63% 308.27% 303.88% 343.98%
Danaher Corp. 123.11% 157.62% 156.95% 187.44% 172.97%
Eli Lilly & Co. 2,281.36% 2,390.18% 1,239.79% 833.40% 778.02%
Gilead Sciences Inc. 276.96% 148.05% 175.26% 119.58% 125.56%
Johnson & Johnson 288.70% 309.06% 288.40% 366.82% 363.75%
Merck & Co. Inc. 231.53% 412.35% 312.72% 223.02% 292.93%
Pfizer Inc. 40.73% 40.45% 124.43% 210.66% 116.68%
Regeneron Pharmaceuticals Inc. 416.61% 663.41% 521.52% 461.61% 508.24%
Thermo Fisher Scientific Inc. 182.22% 189.54% 195.34% 212.01% 232.34%
Vertex Pharmaceuticals Inc. 1,158.91% 712.26% 484.09% 564.91% 575.24%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 MVA. See details »

2 Invested capital. See details »

3 2024 Calculation
MVA spread ratio = 100 × MVA ÷ Invested capital
= 100 × 97,292 ÷ 62,654 = 155.28%

4 Click competitor name to see calculations.

Performance ratio Description The company
MVA spread ratio The ratio of MVA to invested capital. It measures the efficiency with which investors’ capital investment has translated into a franchise value and into an aggregate net present value premium. Bristol-Myers Squibb Co. MVA spread ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 not reaching 2022 level.

MVA Margin

Bristol-Myers Squibb Co., MVA margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Market value added (MVA)1 97,292 67,993 115,404 111,443 99,007
Revenues 48,300 45,006 46,159 46,385 42,518
Performance Ratio
MVA margin2 201.43% 151.08% 250.01% 240.26% 232.86%
Benchmarks
MVA Margin, Competitors3
AbbVie Inc. 594.14% 551.18% 420.74% 432.93% 391.08%
Amgen Inc. 470.63% 555.51% 493.74% 503.37% 550.26%
Danaher Corp. 380.02% 517.54% 389.99% 468.46% 507.10%
Eli Lilly & Co. 1,813.26% 2,058.21% 1,055.66% 769.29% 778.57%
Gilead Sciences Inc. 429.17% 251.89% 295.97% 211.56% 259.24%
Johnson & Johnson 346.20% 359.73% 345.74% 383.60% 433.17%
Merck & Co. Inc. 286.58% 479.92% 390.05% 323.90% 349.01%
Pfizer Inc. 86.91% 105.20% 136.21% 224.83% 284.06%
Regeneron Pharmaceuticals Inc. 365.32% 605.08% 525.04% 312.14% 495.20%
Thermo Fisher Scientific Inc. 348.77% 378.46% 360.17% 431.35% 441.03%
Vertex Pharmaceuticals Inc. 951.31% 955.82% 714.32% 700.10% 754.94%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 MVA. See details »

2 2024 Calculation
MVA margin = 100 × MVA ÷ Revenues
= 100 × 97,292 ÷ 48,300 = 201.43%

3 Click competitor name to see calculations.

Performance ratio Description The company
MVA margin The ratio of MVA to sales. It measures how efficiently and prodigiously sales translate into franchise value. Bristol-Myers Squibb Co. MVA margin ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 not reaching 2022 level.